LLLiang-Yu Lin

Liang-Yu Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liang-Yu Lin has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The association between COVID ‐19 and incident gestational diabetes ( GDM ): A population‐based case–control study of the National Health Insurance Research Database in Taiwan

    by Liang‐Yu Lin, Chi‐Jen Chen, Mei‐Huei Chen, Chun‐Wei Chen, Pau‐Chung Chen

    Background: Reports suggested that diabetes could be a complication arising from COVID‐19; however, the relationship between COVID‐19 and the development of gestational diabetes mellitus (GDM) remains unclear. Objectives: This study aimed to investigate the association between COVID‐19 infections and the risk of incident GDM in pregnant women. Methods: We analyzed data from Taiwan's National Health Insurance Research Database (NHIRD), which is linked to the Birth Reporting Database and the COVID‐19 testing database between 2020 and 2022. A case–control study was conducted, matching pregnant women by age and region. We employed multivariable logistic regression, adjusting for matching factors and potential confounders. The findings were further validated through a sensitivity analysis using a cohort design with landmark analysis. Results: The study included 134,375 pregnant women, comprising 26,875 GDM cases and 107,500 matched controls. After adjusting for covariates, we found no evidence supporting an association between prior COVID‐19 infection and incident GDM (adjusted odds ratio [aOR] = 0.95, 95% confidence interval [CI] = 0.89–1.01). Notably, some evidence showed that receiving at least one COVID‐19 vaccination was associated with a decreased risk of GDM (aOR = 0.90, 95% CI = 0.87–0.93). These results remained consistent in the sensitivity analysis. Conclusion: Despite COVID‐19 now being endemic with less virulent variants, ongoing vigilance regarding potential pregnancy‐related impacts of SARS‐CoV‐2 is essential. It is also critical to promote vaccination among women of childbearing age, and further research is necessary to explore COVID‐19‐related complications during pregnancy.


  • Open Access

    Checklist and guidance on creating codelists for routinely collected health data research

    by Julian Matthewman, Kirsty Andresen, Anne Suffel, Liang-Yu Lin, Anna Schultze, John Tazare, Krishnan Bhaskaran, Elizabeth Williamson, Ruth Costello, Jennifer Quint, et al.

    Background Codelists are required to extract meaningful information on characteristics and events from routinely collected health data such as electronic health records. Research using routinely collected health data relies on codelists to define study populations and variables, thus, trustworthy codelists are important. Here, we provide a checklist, in the style of commonly used reporting guidelines, to help researchers adhere to best practice in codelist development and sharing. Methods Based on a literature search and a workshop with researchers experienced in the use of routinely collected health data, we created a set of recommendations that are 1. broadly applicable to different datasets, research questions, and methods of codelist creation; 2. easy to follow, implement and document by an individual researcher, and 3. fit within a step-by-step process. We then formatted these recommendations into a checklist. Results We have created a 10-step checklist, comprising 28 items, with accompanying guidance on each step. The checklist advises on which metadata to provide, how to define a clinical concept, how to identify and evaluate existing codelists, how to create new codelists, and how to review, check, finalise, and publish a created codelist. Conclusions Use of the checklist can reassure researchers that best practice was followed during the development of their codelists, increasing trust in research that relies on these codelists and facilitating wider re-use and adaptation by other researchers.


  • Top Cited Papers
    Open Access

    Healthcare utilisation in people with long COVID: an OpenSAFELY cohort study

    by Liang-Yu Lin, Alasdair D. Henderson, Oliver Carlile, Iain Dillingham, Ben F. C. Butler-Cole, Michael Marks, Andrew Briggs, Mark Jit, Laurie A. Tomlinson, Chris Bates, et al.

    Background: Long COVID potentially increases healthcare utilisation and costs. However, its impact on the NHS remains to be determined. Methods: This study aims to assess the healthcare utilisation of individuals with long COVID. With the approval of NHS England, we conducted a matched cohort study using primary and secondary care data via OpenSAFELY, a platform for analysing anonymous electronic health records. The long COVID exposure group, defined by diagnostic codes, was matched with five comparators without long COVID between Nov 2020 and Jan 2023. We compared their total healthcare utilisation from GP consultations, prescriptions, hospital admissions, A&E visits, and outpatient appointments. Healthcare utilisation and costs were evaluated using a two-part model adjusting for covariates. Using a difference-in-difference model, we also compared healthcare utilisation after long COVID with pre-pandemic records. Results: We identified 52,988 individuals with a long COVID diagnosis, matched to 264,867 comparators without a diagnosis. In the 12 months post-diagnosis, there was strong evidence that those with long COVID were more likely to use healthcare resources (OR: 8.29, 95% CI: 7.74–8.87), and have 49% more healthcare utilisation (RR: 1.49, 95% CI: 1.48–1.51). Our model estimated that the long COVID group had 30 healthcare visits per year (predicted mean: 29.23, 95% CI: 28.58–29.92), compared to 16 in the comparator group (predicted mean visits: 16.04, 95% CI: 15.73–16.36). Individuals with long COVID were more likely to have non-zero healthcare expenditures (OR = 7.66, 95% CI = 7.20–8.15), with costs being 44% higher than the comparator group (cost ratio = 1.44, 95% CI: 1.39–1.50). The long COVID group costs approximately £2500 per person per year (predicted mean cost: £2562.50, 95% CI: £2335.60–£2819.22), and the comparator group costs £1500 (predicted mean cost: £1527.43, 95% CI: £1404.33–1664.45). Historically, individuals with long COVID utilised healthcare resources more frequently, but their average healthcare utilisation increased more after being diagnosed with long COVID, compared to the comparator group. Conclusions: Long COVID increases healthcare utilisation and costs. Public health policies should allocate more resources towards preventing, treating, and supporting individuals with long COVID.


  • Open Access

    Checklist and guidance on creating codelists for electronic health records research

    by Julian Matthewman, Kirsty Andresen, Anne Suffel, Liang-Yu Lin, Anna Schultze, John Tazare, Krishnan Bhaskaran, Elizabeth Williamson, Ruth Costello, Jennifer Quint, et al.

    Background Codelists are required to extract meaningful information on characteristics and events from electronic health records (EHRs). EHR research relies on codelists to define study populations and variables, thus, trustworthy codelists are important. Here, we provide a checklist, in the style of commonly used reporting guidelines, to help researchers adhere to best practice in codelist development and sharing. Methods Based on a literature search and a workshop with experienced EHR researchers we created a set of recommendations that are 1. broadly applicable to different datasets, research questions, and methods of codelist creation; 2. easy to follow, implement and document by an individual researcher, and 3. fit within a step-by-step process. We then formatted these recommendations into a checklist. Results We have created a 9-step checklist, comprising 26 items, with accompanying guidance on each step. The checklist advises on which metadata to provide, how to define a clinical concept, how to identify and evaluate existing codelists, how to create new codelists, and how to review, finalise, and publish a created codelist. Conclusions Use of the checklist can reassure researchers that best practice was followed during the development of their codelists, increasing trust in research that relies on these codelists and facilitating wider re-use and adaptation by other researchers.


  • Open Access

    Healthcare utilisation in people with long COVID: an OpenSAFELY cohort study

    by Liang-Yu Lin, Alasdair D Henderson, Oliver Carlile, Iain Dillingham, Ben Fc Butler-Cole, Michael Marks, Andrew Briggs, Mark Jit, Laurie A Tomlinson, Chris Bates, et al.

    Background: Long COVID, characterised by various symptoms and complications, potentially increases healthcare utilisation and costs. However, its impact on the NHS remains to be determined. Objective: This study aims to assess the healthcare utilisation of individuals with long COVID. Methods: With the approval of NHS England, we conducted a matched cohort study using primary and secondary care data via OpenSAFELY, a platform for analysing anonymous electronic health records. The long COVID exposure group, defined by diagnostic codes, was matched with five comparators without long COVID between Nov 2020 and Jan 2023. We compared their total healthcare utilisation from GP consultations, prescriptions, hospital admissions, A&E visits, and outpatient appointments. Healthcare utilisation and costs were evaluated using a two-part model adjusting for covariates. Using a difference-in-difference model, we also compared healthcare utilisation after long COVID with pre-pandemic records. Results: We identified 52,988 individuals with a long COVID diagnosis, matched to 264,867 comparators without a diagnosis. In the 12 months post-diagnosis, there was strong evidence that those with long COVID were more likely to use healthcare resources (OR: 8.07, 95% CI: 7.54 – 8.64), and have 49% more healthcare utilisation (RR: 1.49, 95% CI: 1.47 – 1.50). Our model estimated that the long COVID group had 30 healthcare visits per year (predicted mean: 29.23, 95% CI: 28.58 - 29.92), compared to 16 in the comparator group (predicted mean visits: 16.04, 95% CI: 15.73 - 16.36). Individuals with long COVID were more likely to have non-zero healthcare expenditures (OR = 7.47, 95% CI = 7.02 – 7.95), with costs being 43% higher than the comparator group (cost ratio = 1.43, 95% CI: 1.38 – 1.49). The long COVID group costs approximately £2,500 per person per year (predicted mean cost: £2,562.50, 95% CI: £2,335.60 - £2,819.22), and the comparator group costs £1,500 (predicted mean cost: £1,527.43, 95% CI: £1,404.33 - 1,664.45.) Historically, individuals with long COVID utilised healthcare resources more frequently, but their average healthcare utilisation increased more after being diagnosed with long COVID, compared to the comparator group. Conclusion: Long COVID increases healthcare utilisation and costs. Public health policies should allocate more resources towards preventing, treating, and supporting individuals with long COVID.


  • Open Access

    Cohort profile: OpenPROMPT

    by Alasdair D Henderson, Oliver Carlile, Iain Dillingham, Ben Fc Butler-Cole, Keith Tomlin, Mark Jit, Laurie A Tomlinson, Michael Marks, Andrew Briggs, Liang-Yu Lin, et al.

    OpenPROMPT is a cohort of individuals with longitudinal patient reported questionnaire data and linked to routinely collected health data from primary and secondary care. Data were collected between November 2022 and October 2023 in England. OpenPROMPT was designed to measure the impact of long COVID on health-related quality-of-life (HRQoL). With the approval of NHS England we collected responses from 7,574 individuals, with detailed questionnaire responses from 6,337 individuals who responded using a smartphone app. Data were collected from each participant over 90 days at 30-day intervals using questionnaires to ask about HRQoL, productivity and symptoms of long COVID. Responses from the majority of OpenPROMPT (6,006; 79.3%) were linked to participants’ existing health records from primary care, secondary care, COVID-19 testing and vaccination data. Analysis takes place using the OpenSAFELY data analysis platform which provides a secure software interface allowing the analysis of pseudonymized primary care patient records from England. OpenPROMPT can currently be used to estimate the impact of long COVID on HRQoL, and because of the linkage within OpenSAFELY, the data from OpenPROMPT can be used to enrich routinely collected records in further research by approved researchers on behalf of NHS England. Lay summary: OpenPROMPT is a study which used a phone app to conduct a longitudinal survey aimed at measuring the health related quality of life of people living with long COVID. The study recruited participants between November 2022 and July 2023 and followed them up for 90 days. The key advantage of this study is that the responses are linked to the individual’s personal health records, so we have access to much more data than the questionnaire responses alone. Here, we summarised who has used the app, how much data has been collected and the quality of the data. We also provide details to document how and why the data were collected so that the data can be used by other researchers in the future. This will maximise the benefit of this study, and ensure that the time invested by participants is put to best use. In this study we aimed to provide lots of important information about how many people are involved, how much information we have about them, their age, where they live, and how healthy they are. Finally, for certain variables we compared the responses people recorded in the app with what is kept on their electronic record to see if they agree or disagree. Key features: OpenPROMPT is a cohort of individuals with longitudinal patient reported questionnaire data and linked to routinely collected health data from primary and secondary care. With the approval of NHS England we collected responses from 7,574 individuals, with detailed questionnaire responses from 6,337 individuals who responded using a smartphone app. Data were collected from each participant over 90 days at 30-day intervals using questionnaires to ask about HRQoL, productivity and symptoms of long COVID. Responses from the majority of OpenPROMPT (6,006; 79.3%) were linked to participants’ existing health records from primary care, secondary care, COVID-19 testing and vaccination data. OpenPROMPT can currently be used to estimate the impact of long COVID on HRQoL, and because of the linkage within OpenSAFELY, the data from OpenPROMPT can be used to enrich routinely collected records in further research by approved researchers on behalf of NHS England.

  • Open Access

    The impact of Long COVID on Health-Related Quality-of-Life using OpenPROMPT

    by Oliver Carlile, Andrew Briggs, Alasdair D Henderson, Ben Fc Butler-Cole, John Tazare, Laurie Tomlinson, Michael Marks, Mark Jit, Liang-Yu Lin, Chris Bates, et al.

    Background: Long COVID is a major problem affecting patient health, the health service, and the workforce. To optimise the design of future interventions against COVID-19, and to better plan and allocate health resources, it is critical to quantify the health and economic burden of this novel condition. Methods: With the approval of NHS England, we developed OpenPROMPT, a UK cohort study measuring the impact of long COVID on health-related quality-of-life (HRQoL). OpenPROMPT invited responses to Patient Reported Outcome Measures (PROMs) using a smartphone application and recruited between November 2022 and October 2023. We used the validated EuroQol EQ-5D questionnaire with the UK Value Set to develop disutility scores (1-utility) for respondents with and without Long COVID using linear mixed models, and we calculated subsequent Quality-Adjusted Life-Months (QALMs) for long COVID. Results: We used data from 6,070 participants where 24.7% self-reported long COVID. In multivariable regressions, long COVID had a consistent impact on HRQoL, showing a high probability of reporting loss in quality-of-life (OR: 22, 95% CI:12.35-39.29) compared with people who did not report long COVID. Reporting a disability was the largest predictor of losses of HRQoL (OR: 60.2, 95% CI: 27.79-130.57) across survey responses. Self-reported long COVID was associated with an 0.37 QALM loss. Conclusions: We found substantial impacts on quality-of-life due to long COVID, representing a major burden on patients and the health service. We highlight the need for continued support and research for long COVID, as HRQoL scores compared unfavourably to patients with conditions such as multiple sclerosis, heart failure, and renal disease.


  • Open Access

    Protocol for an OpenSAFELY cohort study collecting patient-reported outcome measures using the TPP Airmid smartphone application and linked big data to quantify the health and economic costs of long COVID (OpenPROMPT)

    by Emily Herrett, Keith Tomlin, Liang-Yu Lin, Laurie A Tomlinson, Mark Jit, Andrew Briggs, Michael Marks, Frank Sandmann, John Parry, Christopher Bates, et al.

    Introduction The impact of long COVID on health-related quality of-life (HRQoL) and productivity is not currently known. It is important to understand who is worst affected by long COVID and the cost to the National Health Service (NHS) and society, so that strategies like booster vaccines can be prioritised to the right people. OpenPROMPT aims to understand the impact of long COVID on HRQoL in adults attending English primary care. Methods and analysis We will ask people to participate in this cohort study through a smartphone app (Airmid), and completing a series of questionnaires held within the app. Questionnaires will ask about HRQoL, productivity and symptoms of long COVID. Participants will be asked to fill in the questionnaires once a month, for 90 days. Questionnaire responses will be linked, where possible, to participants’ existing health records from primary care, secondary care, and COVID testing and vaccination data. Analysis will take place using the OpenSAFELY data platform and will estimate the impact of long COVID on HRQoL, productivity and cost to the NHS. Ethics and dissemination The Proportionate Review Sub-Committee of the South Central—Berkshire B Research Ethics Committee has reviewed and approved the study and have agreed that we can ask people to take part (22/SC/0198). Our results will provide information to support long-term care, and make recommendations for prevention of long COVID in the future. Trial registration number NCT05552612.


  • Open Access

    Association between vitamin D and incident herpes zoster: a UK Biobank study

    by Liang-Yu Lin, Rohini Mathur, Amy Mulick, Liam Smeeth, Sinéad M Langan, Charlotte Warren-Gash

    Background: Although vitamin D has immunomodulatory effects, any association with herpes zoster (HZ) is unclear. Aim: To explore the association between vitamin D status and the risk of incident HZ in adults in the UK. Design and setting: We conducted a cohort study including participants from UK Biobank, who had at least one vitamin D testing result with linked primary care electronic health records. Methods: The primary exposure was vitamin D status, categorised as deficient (< 25 nmol/L), insufficient (25–50 nmol/L) or sufficient (≥ 50 nmol/L). The secondary exposures were self-reported vitamin D supplementation at baseline assessment and vitamin D prescription records. The outcome was diagnosed incident HZ, identified from linked primary care or hospital inpatient records. We used Weibull regression, adjusting for potential confounders including demographic factors, comorbidities and immunosuppression. Results: We included 177,572 eligible participants in our analysis with mean follow-up time of 10.1 (SD=1.9) years. No evidence showed that low vitamin D was associated with a higher incidence of HZ, compared with people with sufficient vitamin D (deficient: adjusted hazard ratio [HR] = 0.99, 95% confidence interval [CI] = 0.90–1.10; insufficiency: RR = 1.03, CI = 0.96–1.10.) We found no evidence that vitamin D supplementations or receiving vitamin D prescription was associated with HZ incidence (supplementation: HR = 0.88, CI = 0.67–1.16; prescription: HR = 1.11, CI = 0.91–1.34.) Conclusion: We observed no association of vitamin D status, supplementation or prescription with incident HZ. No evidence supported vitamin D supplementation as a strategy to prevent HZ.


  • Open Access

    The association between vitamin D status and COVID-19 in England: A cohort study using UK Biobank

    by Liang-Yu Lin, Amy Mulick, Rohini Mathur, Liam Smeeth, Charlotte Warren-Gash, Sinéad M. Langan

    Background: Recent studies indicate that vitamin D supplementation may decrease respiratory tract infections, but the association between vitamin D and COVID-19 is still unclear. Objective: To explore the association between vitamin D status and infections, hospitalisation, and mortality due to COVID-19. Methods: We used UK Biobank, a nationwide cohort of 500,000 individuals aged between 40 and 69 years at recruitment between 2006 and 2010. We included people with at least one serum vitamin D test, living in England with linked primary care and inpatient records. The primary exposure was serum vitamin D status measured at recruitment, defined as deficiency at <25 nmol/L, insufficiency at 25–49 nmol/L and sufficiency at ≥ 50 nmol/L. Secondary exposures were self-reported or prescribed vitamin D supplements. The primary outcome was laboratory-confirmed or clinically diagnosed SARS-CoV-2 infections. The secondary outcomes included hospitalisation and mortality due to COVID-19. We used multivariable Cox regression models stratified by summertime months and non-summertime months, adjusting for demographic factors and underlying comorbidities. Results: We included 307,512 participants (54.9% female, 55.9% over 70 years old) in our analysis. During summertime months, weak evidence existed that the vitamin D deficiency group had a lower hazard of being diagnosed with COVID-19 (hazard ratio [HR] = 0.86, 95% confidence interval [CI] = 0.77–0.95). During non-summertime, the vitamin D deficiency group had a higher hazard of COVID-19 compared with the vitamin D sufficient group (HR = 1.14, 95% CI = 1.01–1.30). No evidence was found that vitamin D deficiency or insufficiency was associated with either hospitalisation or mortality due to COVID-19 in any time strata. Conclusion: We found no evidence of an association between historical vitamin D status and hospitalisation or mortality due to COVID-19, along with inconsistent results for any association between vitamin D and diagnosis of COVID-19. However, studies using more recent vitamin D measurements and systematic COVID-19 testing are needed.